Page last updated: 2024-11-04

iproniazid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iproniazid is a monoamine oxidase inhibitor (MAOI) that was originally developed as an anti-tubercular drug. However, it was found to have mood-boosting effects and became the first clinically available antidepressant. Its mechanism of action involves inhibiting the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. This inhibition leads to an increase in the levels of these neurotransmitters, contributing to its antidepressant effects. Iproniazid's importance lies in its historical significance as the first antidepressant, paving the way for the development of other MAOIs and eventually, the selective serotonin reuptake inhibitors (SSRIs) used today. While iproniazid is no longer widely used due to its potential for serious side effects, including liver toxicity, it remains a subject of study for its unique pharmacological properties and its role in understanding the mechanisms of depression.'

rhazinal: from the stem extracts of a Malayan Kopsia teoi; displays potent and unusual anti-mitotic property; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3748
CHEMBL ID92401
CHEBI ID5958
SCHEMBL ID4153
MeSH IDM0011704
PubMed CID12041235
CHEMBL ID66489
MeSH IDM0011704

Synonyms (115)

Synonym
chebi:5958 ,
iproniazide
BRD-K88568253-011-03-3
n'-isopropyl-pyridine-4-carbohydrazide
DIVK1C_000121
KBIO1_000121
n'-(1-methylethyl)pyridine-4-carbohydrazide
iproniazidum [inn-latin]
euphozid
marsalid
yatrozide
iproniazide [inn-french]
brn 0142700
iprazid
isonicotinic acid 2-isopropylhydrazide
iproniazyd [polish]
isonicotinic acid, n'-isopropyl hydrazide
ccris 9177
n'-isopropylisonicotinoylhydrazide
iproniazida [inn-spanish]
p 887
rivivol
einecs 200-218-8
1-isonicotinoyl-2-isopropylhydrazine
D02579
iproniazid (inn)
SPECTRUM_000268
LOPAC0_000643
BPBIO1_000079
cas-305-33-9
NCGC00015565-02
lopac-i-7627
NCGC00015565-01
IDI1_000121
BSPBIO_000071
ro 2-4572
n'-isopropylpyridine-4-carbohydrazide
isonicotinic acid, 2-isopropylhydrazide
marsilid
p887
4-pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide
PRESTWICK2_000176
PRESTWICK3_000176
SPECTRUM5_001437
n'-isopropylisonicotinohydrazide
AN-068/14539031
AB00053568
iproniazid ,
54-92-2
DB04818
BSPBIO_001744
KBIO3_001244
KBIOSS_000748
KBIO2_003316
KBIOGR_000951
KBIO2_005884
KBIO2_000748
SPECTRUM3_000272
PRESTWICK1_000176
SPECTRUM4_000396
PRESTWICK0_000176
NINDS_000121
SPBIO_001992
SPBIO_000576
SPECTRUM2_000468
NCGC00162210-01
HMS2090F08
NCGC00015565-04
bdbm29136
chembl92401 ,
n'-propan-2-ylpyridine-4-carbohydrazide
AKOS006229272
CCG-204730
NCGC00015565-03
propilniazida
ipronid
iproniazid [inn:ban:dcf]
unii-d892hfi3xa
4-22-00-00551 (beilstein handbook reference)
iproniazidum
iproniazyd
d892hfi3xa ,
iproniazida
iproniazid [inn]
iproniazid [who-dd]
iproniazid [mi]
S4856
n'-isopropylisonicotino hydrazide
SCHEMBL4153
AB00053568-12
SY025980
mfcd00153819
n inverted exclamation mark -isopropylisonicotinohydrazide
ipronin
isonicotinic acid n'-isopropylhydrazide
iprazide
n'-isopropylisonicotinohydrazide #
n-isopropyl isonicotinhydrazide
AB00053568_13
DTXSID5023168
CS-0013623
HY-B0886A
SBI-0050623.P003
FT-0768597
DS-7371
Q421368
n'-(propan-2-yl)pyridine-4-carbohydrazide
BRD-K88568253-065-03-9
SDCCGSBI-0050623.P004
NCGC00015565-12
HMS3886E05
A870318
BI164580
CHEMBL66489
rhazinal

Research Excerpts

Overview

Iproniazid (Ipr) is a typical monoamine oxidase (MAO) inhibitor. It also seems capable of inhibiting to a certain extent P-450 mediated metabolism.

ExcerptReferenceRelevance
"Iproniazid (Ipr) is a typical monoamine oxidase (MAO) inhibitor which as well seems capable of inhibiting to a certain extent P-450 mediated metabolism."( Influence of inhibition of the metabolic activation on the mutagenicity of some nitrosamines, triazenes, hydrazines and seniciphylline in Drosophila melanogaster.
Vogel, EW; Zijlstra, JA, 1988
)
1

Actions

Iproniazid was found to inhibit formalin-induced oedema of the foot, dextran-induced Oedema and cotton-pellet-induced granulomatous tissue in the rat. It did not increase the content of noradrenaline in the intestine.

ExcerptReferenceRelevance
"Iproniazid did not increase the content of noradrenaline in the intestine."( Increase of 5-hydroxytryptamine in the rat brain by raunescine.
KARKI, NT; PAASONEN, MK, 1959
)
0.96
"Iproniazid was found to inhibit formalin-induced oedema of the foot, dextran-induced oedema and cotton-pellet-induced granulomatous tissue in the rat. "( Antiphlogistic activity of iproniazid.
SALVATERRA, M; SETNIKAR, I; TEMELCOU, O, 1959
)
1.98

Treatment

Pretreatment with iproniazid resulted in the appearance of a contractile response to alpha-methyltyramine in the guinea-pig vas deferens. Iproniazid treatment was associated with a significant increase in brain 5-hydroxytryptamine (5-HT) concentration.

ExcerptReferenceRelevance
"Iproniazid treatment was associated with a significant increase in brain 5-hydroxytryptamine (5-HT) concentration but in association with tryptophan higher brain 5-HT concentrations were recorded."( Inhibition of drug-induced anorexia in rats by methysergide.
Barrett, AM; McSharry, L, 1975
)
0.98
"Iproniazid pretreatment increased markedly the endogenous noradrenaline content of the mesenteric arteries."( Uptake and metabolism of noradrenaline by the mesenteric arteries of the dog.
Branco, D; Garrett, J, 1977
)
0.98
"The iproniazid pretreatment had no affect on acquisition, or any other performance variable, of the task."( Tryptamine impairs the acquisition of a one-way active avoidance task.
Fletcher, PJ, 1989
)
0.76
"The treatment with iproniazide prevented any alterations in content of amines, caused by the compounds in the rat brain in vivo."( [Importance of the initial monoamine oxidase activity for the development of the activating or inhibiting action of indolylhydrazides].
Arzanunts, EM; Safrazbekian, RR; Sukasian, RS,
)
0.45
"Pretreatment with iproniazid resulted in the appearance of a contractile response to alpha-methyltyramine in the guinea-pig vas deferens."( Examination of the paradoxical lack of responsiveness of the guinea-pig vas deferens to tyramine.
Dowding, T; Rand, MJ; Story, DF, 1989
)
0.6

Toxicity

ExcerptReferenceRelevance
"4 mg/kg - dose 1/4th of LD50 given ip), produced several autonomic, neurological and behavioral effects in mice with peak effects being at 15 min."( Acute neurobehavioural toxicity of phosphamindon and its drug-induced alteration.
Agarwal, AK; Sankaranarayanan, A; Sharma, PL, 1990
)
0.28
" Drug-induced hepatitis is generally divided into two categories: acute hepatitis in which the drug or a metabolite destroys a vital target in the cell; immunoallergic hepatitis in which the drug triggers an adverse immune response directed against the liver."( Drug-induced immunotoxicity.
Beaune, PH; Bonierbale, E; Dansette, PM; Mansuy, D; Minoletti, C; Pessayre, D,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The epinephrine and norepinephrine were administered in such a way that a slow, prolonged rate of absorption was achieved."( Potentiation of epinephrine and norepinephrine by iproniazid.
BOROWITZ, JL; NORTH, WC, 1959
)
0.49
" Dopamine deficiency has been associated with several neurological disorders; it has been shown to have good systemic bioavailability and significant uptake into the CNS following intranasal administration."( Metabolism of dopamine by the nasal mucosa.
Chemuturi, NV; Donovan, MD, 2006
)
0.33

Dosage Studied

Time- and dose-response analyses were undertaken to investigate the effects of the substituted hydrazine monoamine oxidase (MAO) inhibitors iproniazid and nialamide. The excitability of the superior cervical ganglion of the rat was not diminished after a three-day treatment with L-Dopa.

ExcerptRelevanceReference
" The excitability of the superior cervical ganglion of the rat was not diminished after a three-day treatment with L-Dopa, Benseraside (Ro 4-4602/1) and Iproniazid, at a dosage below the toxic level (table I)."( [Endogenous catecholamines and excitability of the superior cervical ganglion of the rat (author's transl)].
Burlet, DB, 1976
)
0.45
"Changes in bath temperature caused changes in the adrenergic responsiveness of rabbit iris dilator muscle as indicated by shifts in dose-response curves along the log axis and changes in maximum responses."( Role of neuronal and extraneuronal factors in temperature mediated responsiveness of adrenoceptors.
Ahlquist, RP; Matheny, JL, 1976
)
0.26
"3 A second cannabis extract (II) with a different ratio of cannabinoids (also administered in dosage equivalent to 10 mg Delta(9)-THC/kg) failed to affect pentobarbitone anaesthesia in mice."( Interaction of cannabis and general anaesthetic agents in mice.
Chesher, GB; Jackson, DM; Starmer, GA, 1974
)
0.25
"Time- and dose-response analyses were undertaken to investigate the effects of the substituted hydrazine monoamine oxidase (MAO) inhibitors iproniazid and nialamide on the following: MAO-A and -B activity; levels of gamma-aminobutyric acid (GABA), alanine (ALA), and the neurotransmitter amines dopamine, noradrenaline, and 5-hydroxytryptamine (serotonin) and their acid metabolites; and the activity of GABA-transaminase and ALA-transaminase."( Effects of two substituted hydrazine monoamine oxidase (MAO) inhibitors on neurotransmitter amines, gamma-aminobutyric acid, and alanine in rat brain.
Baker, GB; Paetsch, PR; Takahashi, S; Todd, KG; Yamada, N, 1993
)
0.49
" However, it is also known to accumulate in various tissues up to several times higher after standard oral dosing and we now have evidence from both in vivo and in vitro experiments with spontaneously hypertensive rats (SHR) that millimolar levels stimulate release of norepinephrine (NE) from vascular sympathetic nerve endings (SNEs)."( A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats.
Lee, JM; Peuler, JD, 2001
)
0.31
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
phenylethylamine degradation I220
superpathway of penicillin, cephalosporin and cephamycin biosynthesis1169
deacetylcephalosporin C biosynthesis444
superpathway of phenylethylamine degradation939
putrescine degradation IV419

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.00480.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)555.15000.11007.190310.0000AID1209455; AID1443980; AID1449628; AID1473738
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)6.85000.00011.753610.0000AID1534711
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)7.97000.00002.015110.0000AID1279146
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)7.50000.00040.764912.5000AID459281
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)5.00000.00071.979812.5000AID459280
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)5.70320.00002.37899.7700AID1140811; AID1142839; AID1190190; AID1201740; AID1224145; AID1279145; AID1280666; AID1292320; AID1301269; AID1320874; AID1323962; AID1334743; AID1336724; AID1374197; AID1378854; AID1378867; AID1390035; AID1406147; AID1407177; AID1427512; AID1436076; AID1437168; AID1453105; AID1460876; AID1465287; AID1465302; AID1485915; AID1506678; AID1517859; AID1534711; AID1557173; AID1568798; AID1569980; AID1657150; AID1667262; AID1694881; AID1709260; AID1736437; AID1740535; AID1757198; AID1798967; AID1802599; AID1826663; AID1851411; AID1857198; AID349909; AID361935; AID409942; AID416572; AID449664; AID461711; AID468863; AID478544; AID497342; AID501517; AID509549; AID514141; AID515170; AID528278; AID551665; AID589434; AID593111; AID599357; AID604279; AID610969; AID619466; AID622913; AID629007; AID637705; AID639308; AID693560; AID733504; AID743813; AID767289
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)5.96330.00001.89149.5700AID1140812; AID1142841; AID1190179; AID1201741; AID1224147; AID1279146; AID1280667; AID1292322; AID1301267; AID1320875; AID1323961; AID1334745; AID1336725; AID1374198; AID1378855; AID1378868; AID1390036; AID1406148; AID1407178; AID1427513; AID1436077; AID1437169; AID1453106; AID1460878; AID1465288; AID1465303; AID1485916; AID1506679; AID1517860; AID1534712; AID1557174; AID1568796; AID1569982; AID1657151; AID1667263; AID1694875; AID1709261; AID1736438; AID1740536; AID1757197; AID1798967; AID1802599; AID1826665; AID1851412; AID1857199; AID1872724; AID349912; AID361936; AID409943; AID416573; AID449665; AID461712; AID468865; AID478547; AID497343; AID501518; AID509550; AID514142; AID515171; AID528279; AID551666; AID589435; AID593110; AID599359; AID604281; AID610970; AID619468; AID622915; AID629008; AID637760; AID639310; AID693561; AID733502; AID743812; AID767288
C-X-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)6.56000.00500.35886.5600AID449664
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)7.50000.01431.37567.5000AID1406148
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (92)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
angiogenesisC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of leukocyte migrationC-X-C chemokine receptor type 3Homo sapiens (human)
apoptotic processC-X-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
regulation of cell adhesionC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 3Homo sapiens (human)
immune responseC-X-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-X-C chemokine receptor type 3Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (58)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 3Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
cell surfaceC-X-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-X-C chemokine receptor type 3Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 3Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (319)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID610970Inhibition of human MAO-B assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1517864Inhibition of Electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID497517Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1557173Inhibition of human recombinant MAO-A using kynuramine as substrate measured after 30 mins by fluorimetric assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1485917Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1465299Inhibition of equine serum BuChE incubated for 15 mins by Ellman's method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID629039Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID1569982Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1568799Inhibition of self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin-T based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1694871Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition and measured for 180 secs by Ellman's method2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1826672Displacement of 2-[125l]-lodomelatonin from QR2 in hamster brain homogenate by radioligand binding assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID349909Inhibition of human recombinant MAO-A assessed as hydrogen peroxide production2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1279145Inhibition of human recombinant MAO-A using p-tyramine substrate after 15 mins by fluorimetric analysis2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1557170Inhibition of equine serum BuChE using S-butyrylthiocholine chloride as substrate incubated for 15 mins by Ellman's method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1374198Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1292322Inhibition of human recombinant MAO-B using kynuramine as substrate after 30 mins by fluorescence spectrophotometry2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1378867Inhibition of recombinant human MAOA using p-tyramine as substrate after 15 mins by Amplex Red dye-based fluorometric method2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1334743Inhibition of human recombinant MAO-A using kynuramine as substrate measured after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1517863Inhibition of equine butyrylcholinesterase using butyrylthiocholine iodide as substrate incubated for 15 mins by Ellman's method2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1279146Inhibition of human recombinant MAO-B using p-tyramine substrate after 15 mins by fluorimetric analysis2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1378854Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red d2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID589435Inhibition of human recombinant MAO-B expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID1453107Selectivity index, ratio of IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1851411Inhibition of human MAO-A assessed as inhibition of H2O2 production using p-tyramine as substrate2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID1465288Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID349912Inhibition of human recombinant MAO-B assessed as hydrogen peroxide production2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1427514Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1568801Disaggregation of Cu2+ induced preformed fibrils of amyloid beta (1 to 42) (unknown origin) at 25 uM preincubated with Cu2+ for 24 hrs followed by compound addition and measured after 24 hrs by thioflavin-T based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1465303Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID459280Inhibition of MAOA in Sprague-Dawley rat brain mitochondria using kynuramine substrate by fluorimetry2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors.
AID478547Inhibition of human recombinant MAO-B assessed as inhibition of production of hydrogen peroxide after 15 mins by the Amplex Red fluorimetric method2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID1569977Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 15 mins by Ellman's method2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1534712Inhibition of human MAO-B preincubated for 15 mins followed by p-tyramine substrate addition and measured after 20 mins by Amplex red reagent based fluorescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID604283Selectivity index, ratio of IC50 for human recombinant MAO-A to human recombinant MAO-B2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID1667259Antioxidant activity assessed as AAPH-induced radical scavenging activity by measuring trolox equivalents for oxygen radical absorbance capacity measured every minute for 90 mins by ORAC-FL assay2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1694872Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition and measured for 180 secs by Ellman's method2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1437173Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity at 1 uM preincubated for 15 mins followed by AAPH addition measured every min for 90 mins by ORAC-FL assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID733504Inhibition of recombinant human MAO-A expressed in baculovirus infected BT1-TN-5B1-4 cells assessed as inhibition of production of hydrogen peroxide from p-tyramine after 15 mins by Amplex Red assay2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID1320872Inhibition of human serum BuChE using butyrylthiocholine as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID409944Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1517860Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1709261Inhibition of recombinant human MAOB using kynuramine as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID461712Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID1657150Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID693561Inhibition of human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1826665Inhibition of human recombinant MAO-B using tyramine as substrate by fluorescence assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID599360Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID589433Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID1436076Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID509550Inhibition of human recombinant MAOB expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID1872724Inhibition of human recombinant MAO-B incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
AID449666Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1334745Inhibition of human recombinant MAO-B using kynuramine as substrate measured after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1569978Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate incubated for 15 mins by Ellman's method2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1736437Inhibition of human MAO-A using p-tyramine as substrate by Amplex Red reagent based fluorescence analysis2020European journal of medicinal chemistry, Mar-15, Volume: 190Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1374194Inhibition of cupric ion-mediated amyloid beta (1 to 42) aggregation at 25 uM after 24 hrs by thioflavin T fluorescence assay relative to control2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1636444Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 114.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1407177Inhibition of human MAO-A using p-tyramine as substrate incubated for 15 mins followed by substrate addition measured for 20 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
AID1140813Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes to IC50 for human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID1485915Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition after 20 mins by Amplex red reagent based fluorimetric method2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID361936Inhibition of human recombinant MAOB2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID449664Inhibition of human recombinant MAOA expressed in BTI cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1224149Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2014Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14
New coumarin derivatives: design, synthesis and use as inhibitors of hMAO.
AID629007Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID416573Inhibition of human recombinant MAOB expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID1569983Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID637760Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID1323961Inhibition of recombinant human MAO-B using p-tyramine as substrate assessed as decrease in H2O2 production incubated for 15 mins by fluorimetric method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID478550Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID1740535Inhibition of recombinant human MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate measured after 15 mins by Amplex red reagent based fluorescence assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1636385Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 137.9 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of 2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1453105Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1059234Lipophilicity, log P of the compound2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1465287Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1190179Inhibition of human recombinant MAO-B using p-tyramine as substrate assessed as H2O2 production after 15 mins by fluorescence assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID767289Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID1292320Inhibition of human recombinant MAO-A using kynuramine as substrate after 30 mins by fluorescence spectrophotometry2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1323962Inhibition of recombinant human MAO-A using p-tyramine as substrate assessed as decrease in H2O2 production incubated for 15 mins by fluorimetric method2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID416572Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID1657151Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID1059231Antitubercular activity against Mycobacterium tuberculosis2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1826663Inhibition of human recombinant MAO-A by fluorescence assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID514141Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID509551Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID1190180Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID610971Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID610969Inhibition of human MAO-A assessed as inhibition of p-tyramine oxidation to p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric method2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
AID1740538Selectivity index, ratio of IC50 for recombinant human MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAOB expressed in baculovirus infected BTI insect cells2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1336724Inhibition of recombinant human MAO-A expressed in baculovirus infected High 5 insect cells using kynuramine as substrate incubated for 30 mins by spectrofluorometric method2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1427512Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorimetric method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1757197Inhibition of human recombinant MAO-B by multimode plate reader assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1427513Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorimetric method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1145383Octanol-water partition coefficient, log P of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity studies on monoamine oxidase inhibitors.
AID619466Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID1694876Selectivity for recombinant human MAO-B over recombinant human MAO-A2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1557169Inhibition of electric eel AChE using acetylthiocholine iodide incubated for 15 mins as substrate by Ellman's method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID501520Selectivity ratio of IC50 for human MAOA to IC50 for human MAOB2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1406147Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1568796Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID468865Inhibition of human recombinant MAOB2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID509549Inhibition of human recombinant MAOA expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
AID629008Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
AID1568800Inhibition of Cu2+-induced amyloid beta (1 to 42 residues) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin-T based fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1407178Inhibition of human MAO-B using p-tyramine as substrate incubated for 15 mins followed by substrate addition measured for 20 mins by fluorescence assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
AID461711Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID693560Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID637705Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
AID528279Inhibition of human recombinant MAO-B expressed in baculovirus infected BT1 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.
AID1460879Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID1826673Permeability of compound in PBS buffer at pH 7.4 by PAMPA-BBB assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID593112Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID361935Inhibition of human recombinant MAOA2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID1709260Inhibition of recombinant human MAOA using kynuramine as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1857199Inhibition of MAO-B (unknown origin) using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by Amplex red fluorescence based microplate reader assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Development of MAO-A and 5-HT
AID1826669Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B using tyramine as substrate2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID1378870Selectivity index, ratio of IC50 for recombinant human MAOA to IC50 for recombinant human MAOB2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1406145Inhibition of human 5-lipoxygenase using arachidonic acid as substrate pretreated for 10 mins followed by substrate and ATP addition and measured after 20 mins by H2DCFDA probe based fluorescence assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1378855Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red d2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID1336725Inhibition of recombinant human MAO-B expressed in baculovirus infected High 5 insect cells using kynuramine as substrate incubated for 30 mins by spectrofluorometric method2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID497343Inhibition of human MAOB by fluorimetry2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID1534711Inhibition of human MAO-A preincubated for 15 mins followed by p-tyramine substrate addition and measured after 20 mins by Amplex red reagent based fluorescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
AID743809Selectivity index, ratio of IC50 for human recombinant microsomal MAO-A to IC50 for human recombinant microsomal MAO-B2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID639308Inhibition of human recombinant MAOA expressed in baculovirus-infected BTI insect cells assessed as conversion of p-tyramine into p-hydroxyphenyl-acetaldehyde after 15 mins by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID1485919Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM after 46 to 48 hrs by thioflavin-T fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID501517Inhibition of human MAOA expressed in BTI insect cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1320875Inhibition of human recombinant MAOB using p-tyramine as substrate incubated for 15 mins by fluorimetric method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID693562Selectivity ratio of IC50 for human MAO-A to IC50 for human MAO-B2012European journal of medicinal chemistry, Dec, Volume: 58Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
AID1436077Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID449665Inhibition of human recombinant MAOB expressed in BTI cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1757198Inhibition of human recombinant MAO-A by multimode plate reader assay2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID551666Inhibition of human recombinant MAOB expressed in baculovirus-infected BTI insect cells after 15 mins by fluorimetric assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
AID1301269Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID1378868Inhibition of recombinant human MAOB using p-tyramine as substrate after 15 mins by Amplex Red dye-based fluorometric method2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID416577Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
AID1851414Selectivity index, ratio of IC50 for inhibition of human MAO-A to IC50 for inhibition of human MAO-B2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID349915Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID733499Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BT1-TN-5B1-4 cells to recombinant human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID1557174Inhibition of human recombinant MAO-B using kynuramine as substrate measured after 30 mins by fluorimetric assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID743813Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1506680Selectivity index, ratio of IC50 for human MAOA to IC50 for human MAOB2017MedChemComm, Feb-01, Volume: 8, Issue:2
Synthesis and evaluation of small molecules bearing a benzyloxy substituent as novel and potent monoamine oxidase inhibitors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1320874Inhibition of human recombinant MAOA using p-tyramine as substrate incubated for 15 mins by fluorimetric method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID497342Inhibition of human MAOA by fluorimetry2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
AID1143483Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by BACTEC 960 assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1667262Inhibition of recombinant human MAOA expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1517859Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID622915Inhibition of human recombinant MAO-B expressed in insect BT1-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine up to 15 mins by amplex red-based fluorometric assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1826670Activation of Nrf2 in human Arec32 cells assessed as concentration required to double luciferase activity measured after 24 hrs2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID593111Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID1320870Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by Ellman's method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1320878Antioxidant activity assessed as AAPH free radical scavenging activity by measuring trolox equivalent by oxygen radical absorbance capacity method2016European journal of medicinal chemistry, Oct-04, Volume: 121New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.
AID1569980Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1465302Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1485914Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 1 to 10 uM preincubated for 15 mins followed by AAPH addition measured every minute for 120 mins by ORAC fluorescein assay2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID459281Inhibition of MAOB in Sprague-Dawley rat brain mitochondria using kynuramine substrate by fluorimetry2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors.
AID1857200Selectivity index, ratio of IC50 for inhibition of MAO-B (unknown origin) to IC50 for inhibition of MAO-A (unknown origin)2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Development of MAO-A and 5-HT
AID515170Inhibition of human recombinant MAOA expressed in baculovirus infected BTI insect cells assessed as hydrogen peroxide production after 15 mins by Amplex red assay2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID1334746Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1460878Inhibition of human recombinant MAOB assessed as reduction in H2O2 production from p-tyramine incubated for 15 mins by Amplex red reagent based fluorimetric method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID1740536Inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate measured after 15 mins by Amplex red reagent based fluorescence assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1437172Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1517856Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI cells2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1142841Inhibition of human recombinant MAO-B expressed in baculovirus infected insect cell microsomes assessed as p-tyramine conversion to resorufin and H2O2 after 15 mins by fluorimetric assay2014European journal of medicinal chemistry, Jun-10, Volume: 80New 2H-chromene-3-carboxamide derivatives: design, synthesis and use as inhibitors of hMAO.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1390035Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1406151Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity pretreated for 15 mins followed by APPH challenge measured every minute for 80 mins by ORAC-FL assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1709264Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity measured every min for 90 mins by ORAC-FL assay2021Bioorganic & medicinal chemistry, 04-01, Volume: 35Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID604281Inhibition of human recombinant MAO-B using p-tyramine substrate by fluorometric method2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID1667263Inhibition of recombinant human MAOB expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1485916Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition after 20 mins by Amplex red reagent based fluorimetric method2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID515171Inhibition of human recombinant MAOB expressed in baculovirus infected BTI insect cells assessed as hydrogen peroxide production after 15 mins by Amplex red assay2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID639312Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID1140812Inhibition of human recombinant MAO-B expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID604279Inhibition of human recombinant MAO-A using p-tyramine substrate by fluorometric method2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.
AID1301270Selectivity index, ratio of IC50 for human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells to IC50 for human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID1280666Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI cells using p-tyramine as substrate after 15 mins by Amplex Red-based fluorescence assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID599357Inhibition of human recombinant MAOA expressed in BTI insect cells using p-tyramine substrate by fluorometric method2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1757199Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2021European journal of medicinal chemistry, Apr-15, Volume: 216Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1374197Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID733502Inhibition of recombinant human MAO-B expressed in baculovirus infected BT1-TN-5B1-4 cells assessed as inhibition of production of hydrogen peroxide from p-tyramine after 15 mins by Amplex Red assay2013European journal of medicinal chemistry, Jan, Volume: 591,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
AID1453106Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID551669Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
AID710369Inhibition of MAO in ip dosed Wistar rat assessed as inhibition of tryptamine hydrochloride-induced seizure administered for 0.5 to 4 hrs prior to tryptamine hydrochloride administration2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.
AID1406148Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1694875Inhibition of recombinant human MAO-B using p-tyramine as substrate preincubated with enzyme for 15 mins followed incubation with substrate for 20 mins by Amplex red reagent based fluorescence based analysis2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1280667Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI cells using p-tyramine as substrate after 15 mins by Amplex Red-based fluorescence assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold.
AID1142839Inhibition of human recombinant MAO-A expressed in baculovirus infected insect cell microsomes assessed as p-tyramine conversion to resorufin and H2O2 after 15 mins by fluorimetric assay2014European journal of medicinal chemistry, Jun-10, Volume: 80New 2H-chromene-3-carboxamide derivatives: design, synthesis and use as inhibitors of hMAO.
AID743812Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a2013European journal of medicinal chemistry, May, Volume: 63Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1460876Inhibition of human recombinant MAOA assessed as reduction in H2O2 production from p-tyramine incubated for 15 mins by Amplex red reagent based fluorimetric method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.
AID1190181Inhibition of amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM after 46 to 48 hrs by thioflavin-T fluorescence method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID1568798Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1851412Inhibition of human MAO-B assessed as inhibition of H2O2 production using p-tyramine as substrate2022Bioorganic & medicinal chemistry letters, 10-15, Volume: 74Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID589434Inhibition of human recombinant MAO-A expressed in BTI-TN-5B1-4 cells assessed as H2O2 production using para-tyramine substrate by fluorimetric method2011European journal of medicinal chemistry, Apr, Volume: 46, Issue:4
Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.
AID619471Selectivity ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID1292324Selectivity ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1201745Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID1826671Antioxidant activity assessed as trolox equivalent of ORAC radical scavenging activity preincubated for 15 mins followed by AAPH addition by ORAC-FL assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID1323963Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B incubated for 15 mins2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1374193Inhibition of self-induced aggregation of amyloid beta (1 to 42) (unknown origin) at 25 uM after 24 hrs by thioflavin T fluorescence method relative to control2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID593110Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
AID767288Inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID1279147Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID1301267Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample2016European journal of medicinal chemistry, Jul-19, Volume: 117(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
AID1437168Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID528278Inhibition of human recombinant MAO-A expressed in baculovirus infected BT1 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.
AID1201740Inhibition of human MAO-A using p-tyramine as substrate assessed as H2O2 production by amplex red assay2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID468868Selectivity, ratio of IC50 for human recombinant MAOA to human recombinant MAOB2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID461713Selectivity for human MAOB over human MAOA2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID622913Inhibition of human recombinant MAO-A expressed in insect BT1-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine up to 15 mins by amplex red-based fluorometric assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID1506679Inhibition of human MAOB incubated for 15 mins using p-tyramine substrate by Amplex red reagent based fluorescence assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Synthesis and evaluation of small molecules bearing a benzyloxy substituent as novel and potent monoamine oxidase inhibitors.
AID619468Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
AID514142Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID1694881Inhibition of recombinant human MAO- A using p-tyramine as substrate preincubated with enzyme for 15 mins followed incubation with substrate for 20 mins by Amplex red reagent based fluorescence based analysis2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID599359Inhibition of human recombinant MAOB expressed in BTI insect cells using p-tyramine substrate by fluorometric method2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID361939Ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
AID767285Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
AID1140811Inhibition of human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
AID1190190Inhibition of human recombinant MAO-A using p-tyramine as substrate assessed as H2O2 production after 15 mins by fluorescence assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID1437169Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1465296Inhibition of electric eel AChE using acetylthiocholine as substrate incubated for 15 mins by Ellman's method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1224147Inhibition of human recombinant MAO-B assessed as H2O2 production using p-tyramine substrate by fluorimetric method2014Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14
New coumarin derivatives: design, synthesis and use as inhibitors of hMAO.
AID639310Inhibition of human recombinant MAOB expressed in baculovirus-infected BTI insect cells assessed as using transformed p-tyramine after 15 mins by fluorimetric assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Hydroxycoumarins as selective MAO-B inhibitors.
AID1857198Inhibition of MAO-A (unknown origin) using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by Amplex red fluorescence based microplate reader assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Development of MAO-A and 5-HT
AID1224145Inhibition of human recombinant MAO-A assessed as H2O2 production using p-tyramine substrate by fluorimetric method2014Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14
New coumarin derivatives: design, synthesis and use as inhibitors of hMAO.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID468863Inhibition of human recombinant MAOA2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
AID1506678Inhibition of human MAOA incubated for 15 mins using p-tyramine substrate by Amplex red reagent based fluorescence assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Synthesis and evaluation of small molecules bearing a benzyloxy substituent as novel and potent monoamine oxidase inhibitors.
AID1378858Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN5B1-4 cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN5B1-4 cells2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.
AID1736438Inhibition of human MAO-B using p-tyramine as substrate by Amplex Red reagent based fluorescence analysis2020European journal of medicinal chemistry, Mar-15, Volume: 190Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID515175Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
AID514145Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
AID1145384Ratio of compound to iproniazid for in vivo inhibition of monoamine oxidase in rat brain assessed as increase in serotonin production after 16 hrs1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity studies on monoamine oxidase inhibitors.
AID551665Inhibition of human recombinant MAOA expressed in baculovirus-infected BTI insect cells after 15 mins by fluorimetric assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
AID1142843Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2014European journal of medicinal chemistry, Jun-10, Volume: 80New 2H-chromene-3-carboxamide derivatives: design, synthesis and use as inhibitors of hMAO.
AID1390039Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1336728Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected High 5 insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected High 5 insect cells2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1201741Inhibition of human MAO-B using p-tyramine as substrate assessed as H2O2 production by amplex red assay2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID501518Inhibition of human MAOB expressed in BTI insect cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.
AID1390036Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1657140Inhibition of HFIP-pretreated self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM measured after 24 hrs by ThT fluorescence assay relative to control2020Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID478544Inhibition of human recombinant MAO-A assessed as inhibition of production of hydrogen peroxide after 15 mins by Amplex Red fluorimetric method2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
AID622917Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1802599MAO-A/MAO-B Inhibition Assay from Article 10.1016/j.bioorg.2017.02.016: \\Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer'2017Bioorganic chemistry, 04, Volume: 71Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
AID1798967MAO Enzyme Inhibition Assay from Article 10.1021/jm801590u: \\Chalcones: a valid scaffold for monoamine oxidases inhibitors.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID311668Cytotoxicity against vincristine-resistant human KB/VJ300 cells in presence of 0.121 uM vincristine2007Journal of natural products, Nov, Volume: 70, Issue:11
Biologically active aspidofractinine, rhazinilam, akuammiline, and vincorine alkaloids from Kopsia.
AID1329365Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID311667Cytotoxicity against vincristine-resistant human KB/VJ300 cells2007Journal of natural products, Nov, Volume: 70, Issue:11
Biologically active aspidofractinine, rhazinilam, akuammiline, and vincorine alkaloids from Kopsia.
AID1329362Antibacterial activity against Enterococcus faecalis ATCC 10541 after 24 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID1329364Antibacterial activity against Staphylococcus aureus ATCC 25922 after 24 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID1329363Antibacterial activity against Escherichia coli ATCC 11775 after 24 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID1329361Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth microdilution method2016Journal of natural products, 09-23, Volume: 79, Issue:9
Melokhanines A-J, Bioactive Monoterpenoid Indole Alkaloids with Diverse Skeletons from Melodinus khasianus.
AID311666Cytotoxicity against vincristine-resistant human KB cells2007Journal of natural products, Nov, Volume: 70, Issue:11
Biologically active aspidofractinine, rhazinilam, akuammiline, and vincorine alkaloids from Kopsia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,636)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901489 (91.01)18.7374
1990's22 (1.34)18.2507
2000's20 (1.22)29.6817
2010's88 (5.38)24.3611
2020's17 (1.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.23 (24.57)
Research Supply Index7.49 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index79.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (0.45%)5.53%
Trials0 (0.00%)5.53%
Reviews38 (2.13%)6.00%
Reviews0 (0.00%)6.00%
Case Studies13 (0.73%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,726 (96.69%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]